Vax myocarditis after COVID similar to other vaccines

Not only is the incidence of myocardial pericarditis after COVID vaccination very low, but it is comparable to non-COVID vaccines, with systematic reviews and meta-analyses found.

An analysis of 11 studies with more than 400 million vaccinations showed no significant difference in the incidence of myocardial pericarditis after vaccination with COVID and non-COVID vaccines (18.2 cases per million vaccinations). And 56.0 cases, P= 0.20), reported by Kollengode Ramanathan, MD, and colleagues at the National University Hospital in Singapore.

In addition, there was no significant difference in the incidence of myocardial pericarditis after influenza vaccination compared to COVID vaccination (1.3 times per million). P= 0.43), they wrote Lancet Respiratory Medicine..

“The development of myocardial pericarditis after non-COVID-19 vaccination is a side effect of the inflammatory process in which myocardial pericarditis is induced by vaccination and is a COVID-19 vaccine or SARS-CoV-2 spike protein for infections. It may suggest that it is not specific to the disease, “co-author Joti Somani, a doctor of medicine, said in a statement from the National University Hospital.

In fact, Ramanasan’s group said that prior to the COVID vaccine, the only vaccine associated with an increased risk of myocardial pericarditis was the smallpox vaccine.

“It is not definitive whether these findings reflect a true increase in incidence or simply an improvement in reporting and recall bias,” they wrote.

They searched studies from January 1, 1947 to December 31, 2021 and showed key results in the incidence of myocardial pericarditis in the temporal relationship with vaccination.

Overall, the incidence of post-vaccination myocardial pericarditis in 22 studies was 33 per million doses (95% CI 15.3-72.6).

Myocardial pericarditis after smallpox vaccination was significantly higher than COVID vaccination (132.1 cases per million people).P<0.001).

Among the COVID vaccines, the incidence of myocardial pericarditis was not significantly different between the adult and pediatric subgroups (26.0 vs. 18.4 cases / million, P= 0.58).

As confirmed in other studies, the incidence of myocardial pericarditis is significantly higher among those vaccinated with the mRNA vaccine (22.6 cases per million doses) and higher in those under the age of 30 (100). 40.9 cases per 10,000 times), which was higher in men than in women (23 vs. 5.1 million). The authors emphasized that “these findings are an important addition to the conversation when weighing the risks and benefits of COVID-19 vaccination during this pandemic.”

Ramanasan’s group also found that mortality from all pooled causes was not significant when comparing the COVID vaccine (8.4 per million) with the non-COVID vaccine (7.2 per million). bottom. P= 0.93).

so Ancillary editorialMargaret Ryan and Jamon Gomery, MD, of the Department of Defense and Health in Falls Church, Virginia, described post-vaccination myocardial pericarditis as “unexpected, but not unprecedented.”

They stated that there was a “common demographic and clinical feature” between smallpox and cases of myocardial pericarditis associated with the mRNA COVID vaccine. In fact, Ryan and Montgomery were the first U.S. military experts (“many young men”) familiar with post-smallpox vaccination adverse events (AEs) to “case myocarditis after mRNA COVID”. He is one of the people who observed it. ” -19 Vaccines ”, given the high likelihood of receiving a double-dose vaccine series in early 2021.

The editors also discussed the lack of information on post-immunization myocarditis other than smallpox or COVID, and a 75-year literature review found only five publications.

“There may be no published literature in the population with little or no myocardial pericarditis observed after billions of vaccinations. From the background population. Reassuring data is not incorporated into the analysis of the literature, “they write. It is important to thoroughly investigate these AEs, given their association with vaccine reliability.

“Alternative vaccine platforms, vaccine doses, or vaccine schedules may reduce the risk of rare adverse events and should be investigated in the context of changing risk of infection,” Ryan and Montgomery added. ..

The limitations of the study include that the findings cannot be generalized to children under the age of 12 who received the COVID vaccine, and that the vaccines were compared over different periods of time, which could lead to potential confounders. It was. Finally, a vaccine against hepatitis, Haemophilus influenzaeStreptococcus pneumoniae and diphtheria, whooping cough and tetanus were underestimated in literature reviews.